Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 17/20 | 0.70 |
| ▸ | ESR2 | Q92731 | 9/20 | 0.70 |
| ▸ | AR | P10275 | 4/20 | 0.70 |
| ▸ | VDR | P11473 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29492899 | 1.00 | ESR1 (0.70) | ESR1ESR2ARVDRTP53 | |
| SCHEMBL4401972 | 0.86 | ESR1 (0.52) | ESR1ESR2ARTDP1 | |
| SCHEMBL56223 | 0.85 | ALDH1A1 (0.61) | ESR1ESR2ARTDP1 | |
| SCHEMBL29499858 | 0.83 | ESR1 (0.70) | ESR1ESR2ARVDRTP53 | |
| SCHEMBL11319965 | 0.83 | ESR1 (0.70) | ESR1ESR2ARVDRTP53 | |
| SCHEMBL30596871 | 0.83 | ESR1 (0.70) | ESR1ESR2ARVDRTP53 | |
| SCHEMBL312794 | 0.83 | ESR1 (0.70) | ESR1ESR2ARVDRTP53 | |
| SCHEMBL30058620 | 0.83 | ESR1 (1.00) | ESR1ESR2ARVDR | |
| SCHEMBL837374 | 0.83 | ESR1 (1.00) | ESR1ESR2ARVDR | |
| SCHEMBL80891 | 0.82 | MAPK1 (0.48) | ESR1ESR2ARTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070056901-A1 | Solvent-resistant membranes from solvent-inert polyimides and polyketones | GENERAL ELECTRIC COMPANY | 2007-03-15 | — | — | US | claimed |
| US-20250388541-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4511117-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | Vertex Pharmaceuticals Incorporated (US) | 2025-02-26 | — | — | EP | disclosed |
| EP-4511114-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | Vertex Pharmaceuticals Incorporated (US) | 2025-02-26 | — | — | EP | disclosed |
| US-20240219830-A1 | SALT, ACID GENERATOR, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2024-07-04 | — | — | US | disclosed |
| US-20240210824-A1 | CARBOXYLATE, CARBOXYLIC ACID GENERATOR, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2024-06-27 | — | — | US | disclosed |
| EP-3377473-B1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2024-06-19 | — | — | EP | disclosed |
| US-11874601-B2 | Resist composition, method of forming resist pattern, compound, and acid diffusion-controlling agent | TOKYO OHKA KOGYO CO., LTD. (JP) | 2024-01-16 | — | — | US | disclosed |
| US-11840503-B2 | Salt, acid generator, resist composition and method for producing resist pattern | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-12-12 | — | — | US | disclosed |
| US-11835857-B2 | Resist composition and method of forming resist pattern | TOKYO OHKA KOGYO CO., LTD. (JP) | 2023-12-05 | — | — | US | disclosed |
| US-20070060688-A1 | Solvent-resistant membranes from solvent-inert polyimides and polyketones | GENERAL ELECTRIC COMPANY | 2007-03-15 | — | — | US | disclosed |
| US-20070056901-A1 | Solvent-resistant membranes from solvent-inert polyimides and polyketones | GENERAL ELECTRIC COMPANY | 2007-03-15 | — | — | US | disclosed |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-02-22 | — | — | US | disclosed |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-0733695-A1 | Mannich base derivatives, and the production and uses thereof | ETHYL CORPORATION (US) | 1996-09-25 | — | — | EP | disclosed |
| US-5558683-A | FUEL ADDITIVE | ETHYL CORPORATION (US) | 1996-09-24 | — | — | US | disclosed |
| US-5387266-A | Detergent-dispersant additives for fuels and lubricants | ETHYL CORPORATION (US) | 1995-02-07 | — | — | US | disclosed |
| US-4219570-A | Insect repellents and a method of repelling insects | AJINOMOTO COMPANY, INCORPORATED (JP) | 1980-08-26 | — | — | US | disclosed |
| US-4013640-A | SOLVENT EXTRACTION, DISTILLATION | UNION CARBIDE CORPORATION (US) | 1977-03-22 | — | — | US | disclosed |
| US-3998804-A | PROCESS FOR COUPLING OF WATER-INSOLUBLE 2,4-DISUBSTITUTED PHENOLS WITH DIAZOTIZED O-NITROANILINES | CIBA-GEIGY CORPORATION (US) | 1976-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240210824-A1 | CARBOXYLATE, CARBOXYLIC ACID GENERATOR, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN | SCO2, CBR1, OXGR1 | ESR1 801/4885ESR2 1960/4885AR 2165/4885 |
| US-20250388541-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | SCN1B, CLIC1, HCN1 | ESR1 4705/4885ESR2 2963/4885AR 2675/4885 |
| US-11874601-B2 | Resist composition, method of forming resist pattern, compound, and acid diffusion-controlling agent | MRPS23, MRPS22, SLC11A2 | ESR1 1351/4885ESR2 806/4885AR 716/4885 |
| US-20240219830-A1 | SALT, ACID GENERATOR, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN | H1-0, HCN3, RER1 | ESR1 1780/4885ESR2 3148/4885AR 2250/4885 |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | TYR, XDH, XPA | ESR1 3695/4885ESR2 2631/4885AR 254/4885 |
| US-11840503-B2 | Salt, acid generator, resist composition and method for producing resist pattern | RER1, H1-0, CA7 | ESR1 1209/4885ESR2 2661/4885AR 1355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.